Anixa Biosciences announces Phase 2 study for breast cancer vaccine

Anixa Biosciences announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by a grant from the U.S. Department of Defense. The proposed Phase 2 trial will evaluate the efficacy of the vaccine administered in the neoadjuvant setting, in combination with chemotherapy and Keytruda. Compared with primary prevention, the development path for breast cancer treatment is expected to have a shorter path to approval. The key objectives of the trial include evaluating the immunological response to the vaccine and comparing clinical efficacy of standard of care therapy alone with the vaccine plus standard of care therapy. The trial is expected to commence in 2025 and is projected to last approximately two to three years. Immunological responses to the vaccine will be made available as the trial advances.